<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Siemens Healthineers Ag — News on 6ix</title>
<link>https://6ix.com/company/siemens-healthineers-ag</link>
<description>Latest news and press releases for Siemens Healthineers Ag on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 17 Apr 2026 14:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/siemens-healthineers-ag" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69da213ed20c3ebdd611e269.webp</url>
<title>Siemens Healthineers Ag</title>
<link>https://6ix.com/company/siemens-healthineers-ag</link>
</image>
<item>
<title>ScreenPoint Medical Secures $16M to Lead the Next Phase of AI in Breast Cancer Care</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/screenpoint-medical-secures-dollar16m-to-lead-the-next-phase-of-ai-in-breast-cancer-care</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/screenpoint-medical-secures-dollar16m-to-lead-the-next-phase-of-ai-in-breast-cancer-care</guid>
<pubDate>Fri, 17 Apr 2026 14:00:00 GMT</pubDate>
<description>ScreenPoint Medical, a leader in artificial intelligence solutions for breast cancer detection and risk assessment, today announced $14 million in new funding from existing investors, global software investor Insight Partners and Siemens Healthineers, in addition to $2 million in non-dilutive research grants.</description>
</item>
<item>
<title>Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with Siemens Healthineers for the Transformative Bio-Hermes-002 Study</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/global-alzheimers-platform-foundation-announces-strategic-collaboration-and-partnership-with-siemens-healthineers-for-the-transformative-bio-hermes-002-study</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/global-alzheimers-platform-foundation-announces-strategic-collaboration-and-partnership-with-siemens-healthineers-for-the-transformative-bio-hermes-002-study</guid>
<pubDate>Thu, 09 Apr 2026 13:00:00 GMT</pubDate>
<description>Siemens Healthineers joins collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer's disease and dementiasWASHINGTON, April 09, 2026 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Siemens Healthineers, a leading global medical technology provider pioneering breakthroughs in healthcare, to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study that compares blood-based and di</description>
</item>
<item>
<title>Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/radiopharm-theranostics-and-siemens-healthineers-sign-clinical-supply-agreement-for-rad101-in-the-us-1</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/radiopharm-theranostics-and-siemens-healthineers-sign-clinical-supply-agreement-for-rad101-in-the-us-1</guid>
<pubDate>Tue, 07 Apr 2026 11:00:00 GMT</pubDate>
<description>Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, with 90% concordance (Primary Endpoint) with MRI. Partnership ensures sufficient supply of RAD 101 in Phase 3 registrational trial in the U.S. SYDNEY, April 07, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of hig</description>
</item>
<item>
<title>Imaginostics Receives Siemens Healthineers Letter of Support as Companies Advance Quantitative MRI Dialogue</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/imaginostics-receives-siemens-healthineers-letter-of-support-as-companies-advance-quantitative-mri-dialogue</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/imaginostics-receives-siemens-healthineers-letter-of-support-as-companies-advance-quantitative-mri-dialogue</guid>
<pubDate>Fri, 20 Mar 2026 20:17:00 GMT</pubDate>
<description>ORLANDO, Fla., March 20, 2026--Imaginostics, Inc. today announced that it has received a Letter of Support from Siemens Healthineers in connection with ongoing exploratory discussions regarding potential collaboration in quantitative MRI and imaging biomarkers.</description>
</item>
<item>
<title>Siemens Healthineers Launches Brain Health Research Portfolio with First Biomarker Assays Now Available</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/siemens-healthineers-launches-brain-health-research-portfolio-with-first-biomarker-assays-now-available</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/siemens-healthineers-launches-brain-health-research-portfolio-with-first-biomarker-assays-now-available</guid>
<pubDate>Wed, 18 Mar 2026 12:30:00 GMT</pubDate>
<description>Brain-derived, fully automated Atellica IM Phosphorylated tau 217 (pTau217) and Atellica IM Brain Derived Tau (BDTau) assays now available for research use Brain Image Siemens Healthineers announced today its offerings for brain health research are expanding, with the brain-derived, fully automated Atellica IM Phosphorylated tau 217 (pTau217) and Atellica IM Brain Derived Tau (BDTau) assays now available for research use. Tarrytown, New York, USA, March 18, 2026 (GLOBE NEWSWIRE) -- Research assa</description>
</item>
<item>
<title>First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleared by FDA for Advanced Soft-Tissue Diagnostics</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/first-ever-dental-dedicated-mri-validated-in-clinical-trial-and-cleared-by-fda-for-advanced-soft-tissue-diagnostics</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/first-ever-dental-dedicated-mri-validated-in-clinical-trial-and-cleared-by-fda-for-advanced-soft-tissue-diagnostics</guid>
<pubDate>Mon, 09 Mar 2026 12:30:00 GMT</pubDate>
<description>Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United States. This milestone follows the completion of a clinical trial2 validating the system’s significant potential across multiple dental specialties. The trial highlighted this first-of-its-kind technology’s applicability in endodontics, periodontics, TMJ, tooth extraction, and orthodontics, offering</description>
</item>
<item>
<title>Onapsis CEO Joins Industry Leaders on the Main Stage at SAPinsider Las Vegas 2026</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/onapsis-ceo-joins-industry-leaders-on-the-main-stage-at-sapinsider-las-vegas-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/onapsis-ceo-joins-industry-leaders-on-the-main-stage-at-sapinsider-las-vegas-2026-1</guid>
<pubDate>Thu, 05 Mar 2026 14:00:00 GMT</pubDate>
<description>BOSTON, March 05, 2026--Onapsis, the global leader in SAP cybersecurity and compliance, today announced its premier Double Platinum sponsorship of SAPinsider Las Vegas 2026, taking place March 16–19 at the Bellagio Resort & Hotel. As a cornerstone of this year’s event, Onapsis will lead the conversation on securing the modern SAP landscape through a mainstage keynote, deep-dive technical sessions and real-world customer case studies.</description>
</item>
<item>
<title>Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/cortechsai-and-siemens-healthineers-partner-to-expand-global-access-to-neuroquantr-technologies</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/cortechsai-and-siemens-healthineers-partner-to-expand-global-access-to-neuroquantr-technologies</guid>
<pubDate>Wed, 04 Mar 2026 10:06:00 GMT</pubDate>
<description>Cortechs.ai, a global leader in AI-powered neuroimaging solutions, today announced a strategic partnership with Siemens Healthineers to integrate and distribute Cortechs.ai's FDA-cleared NeuroQuant® Lesion Surveillance through the Siemens Healthineers Digital Marketplace. The collaboration is designed to accelerate the worldwide adoption of quantitative brain imaging, improving diagnostic precision, optimizing clinical workflows, and ultimately enhancing patient care in neurology, especially for</description>
</item>
<item>
<title>PENTAX Medical Announces Strategic Presence at Connect Labs by Wexford in The Pearl Innovation District to Advance Endoscopic Innovation and Clinical Education</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/pentax-medical-announces-strategic-presence-at-connect-labs-by-wexford-in-the-pearl-innovation-district-to-advance-endoscopic-innovation-and-clinical-education</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/pentax-medical-announces-strategic-presence-at-connect-labs-by-wexford-in-the-pearl-innovation-district-to-advance-endoscopic-innovation-and-clinical-education</guid>
<pubDate>Tue, 03 Feb 2026 15:00:00 GMT</pubDate>
<description>PENTAX Medical, a global leader in endoscopic imaging, has announced a strategic presence at The Pearl, Charlotte's Innovation District, a partnership between Atrium Health and Wexford Science & Technology, LLC. PENTAX Medical will occupy an engineering lab for R&D and showcase equipment, and an office within Connect Labs by Wexford, a flexible, scale-in-place lab and innovation infrastructure that facilitates frictionless entry into the Charlotte innovation ecosystem. PENTAX Medical joins world</description>
</item>
<item>
<title>MASHNET Announces Founding of MASLD Diagnostic Coalition</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/mashnet-announces-founding-of-masld-diagnostic-coalition-1</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/mashnet-announces-founding-of-masld-diagnostic-coalition-1</guid>
<pubDate>Tue, 03 Feb 2026 14:38:00 GMT</pubDate>
<description>MASHNET, a liver Network of Excellence powered by Petauri Kinect, announced today the formation of the MASLD Diagnostic Coalition, a multistakeholder collaboration united by a shared goal to advance access and awareness of non-invasive diagnostics for metabolic dysfunction-associated steatotic liver disease (MASLD).</description>
</item>
<item>
<title>Avanos Medical and Siemens Healthineers Collaborate to Advance Integrated Solutions for Outpatient and Interventional Pain Management</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/avanos-medical-and-siemens-healthineers-collaborate-to-advance-integrated-solutions-for-outpatient-and-interventional-pain-management</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/avanos-medical-and-siemens-healthineers-collaborate-to-advance-integrated-solutions-for-outpatient-and-interventional-pain-management</guid>
<pubDate>Tue, 20 Jan 2026 13:00:00 GMT</pubDate>
<description>Avanos Medical, Inc. (NYSE: AVNS) and Siemens Healthineers today announced a strategic co-marketing agreement to advance outpatient and interventional pain care through an integrated ecosystem of imaging and radiofrequency ablation (RFA) technologies.</description>
</item>
<item>
<title>Carna Health Secures $8 Million to Expand Access to Scalable Chronic Kidney Disease Screening Solutions Globally</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/carna-health-secures-dollar8-million-to-expand-access-to-scalable-chronic-kidney-disease-screening-solutions-globally</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/carna-health-secures-dollar8-million-to-expand-access-to-scalable-chronic-kidney-disease-screening-solutions-globally</guid>
<pubDate>Thu, 08 Jan 2026 14:00:00 GMT</pubDate>
<description>BOSTON, January 08, 2026--Carna Health, a digital health company revolutionizing kidney care, today announced an $8M capital raise to expand global access to its kidney screening technology. The round included participation from Dr. Jay Rosan, Cenk Bekmezçi, Jose Pereyra, Mark Boulding, Brandon Salomon, Andrew Roosevelt, Jeff Lindsey, Joseph White, John Brooks, Elvis Ndansi and Dr. Salvatore Viscomi.</description>
</item>
<item>
<title>ALZpath and Siemens Healthineers Sign Licensing Agreement to Advance Global Access to Blood-Based Alzheimer's Disease Diagnostic Testing</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/alzpath-and-siemens-healthineers-sign-licensing-agreement-to-advance-global-access-to-blood-based-alzheimers-disease-diagnostic-testing</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/alzpath-and-siemens-healthineers-sign-licensing-agreement-to-advance-global-access-to-blood-based-alzheimers-disease-diagnostic-testing</guid>
<pubDate>Mon, 15 Dec 2025 13:30:00 GMT</pubDate>
<description>ALZpath, Inc., a leading developer of innovative diagnostic tools for Alzheimer's disease and related dementias, today announced a licensing agreement with Siemens Healthineers for use of its proprietary pTau217 antibody in the development of a pTau217 assay in the expanding menu of Siemens Healthineers in vitro diagnostic (IVD) tests for Alzheimer's disease.1 The test is being designed for use on Siemens Healthineers' Atellica immunoassay systems.</description>
</item>
<item>
<title>Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/telix-and-varian-announce-strategic-theranostics-ebrt-clinical-collaboration</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/telix-and-varian-announce-strategic-theranostics-ebrt-clinical-collaboration</guid>
<pubDate>Wed, 10 Dec 2025 19:30:00 GMT</pubDate>
<description>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinical applications that combine Telix's theranostic products and external beam radiation therapy (EBRT).</description>
</item>
<item>
<title>Akumin Expands Akumin AXIS™ Line with New 1.5T MRI and Akumin AXIS Drop Trailer</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/akumin-expands-akumin-axistm-line-with-new-15t-mri-and-akumin-axis-drop-trailer</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/akumin-expands-akumin-axistm-line-with-new-15t-mri-and-akumin-axis-drop-trailer</guid>
<pubDate>Mon, 01 Dec 2025 18:00:00 GMT</pubDate>
<description>PLANTATION, Fla., December 01, 2025--Akumin today announced the debut of two major advancements in its Akumin AXIS™ line of relocatable imaging suites at the 2025 Radiological Society of North America (RSNA) annual meeting. The company unveiled the Akumin AXIS 1.5T MRI and introduced the Akumin AXIS Drop Trailer (patent-pending), the first design of its kind in the U.S. and a new evolution in Akumin’s industry-leading mobile imaging portfolio.</description>
</item>
<item>
<title>Stratasys Expands Availability of RadioMatrix™ Radiopaque Material to the United States</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/stratasys-expands-availability-of-radiomatrixtm-radiopaque-material-to-the-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/stratasys-expands-availability-of-radiomatrixtm-radiopaque-material-to-the-united-states</guid>
<pubDate>Mon, 01 Dec 2025 13:15:00 GMT</pubDate>
<description>MINNETONKA, Minn. & REHOVOT, Israel, December 01, 2025--Stratasys Ltd. (NASDAQ: SSYS) today announced full commercial availability of its RadioMatrix™ radiopaque 3D printing material in the United States. This milestone follows initial limited deployments and marks the first time healthcare providers, device manufacturers, and research institutions across the U.S. can broadly access and utilize the material for advanced medical imaging and training applications.</description>
</item>
<item>
<title>Vascular Imaging Market worth US$4.54 billion by 2030 with 7.3% CAGR | MarketsandMarkets™</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/vascular-imaging-market-worth-usdollar454-billion-by-2030-with-73percent-cagr-or-marketsandmarketstm</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/vascular-imaging-market-worth-usdollar454-billion-by-2030-with-73percent-cagr-or-marketsandmarketstm</guid>
<pubDate>Wed, 19 Nov 2025 15:30:00 GMT</pubDate>
<description>The global Vascular Imaging Market, valued at US$3.03 billion in 2024, stood at US$3.19 billion in 2025 and is projected to advance at a resilient CAGR of 7.3% from 2025 to 2030, culminating in a forecasted valuation of US$4.54 billion by the end of the period. The increasing worldwide burden of cardiovascular illnesses, such as peripheral artery disease, coronary artery disease, and stroke, which is caused by lifestyle-related risk factors like smoking, obesity, diabetes, and hypertension, is t</description>
</item>
<item>
<title>Cohen Veterans Bioscience Selects Siemens Healthineers as Partner to expand the National Normative Neuroimaging Library (NNL)</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/cohen-veterans-bioscience-selects-siemens-healthineers-as-partner-to-expand-the-national-normative-neuroimaging-library-nnl</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/cohen-veterans-bioscience-selects-siemens-healthineers-as-partner-to-expand-the-national-normative-neuroimaging-library-nnl</guid>
<pubDate>Tue, 11 Nov 2025 23:41:00 GMT</pubDate>
<description>Cohen Veterans Bioscience, Inc. (CVB), a non-profit 501(c)(3) biomedical research and technology organization and Siemens Healthineers AG (SMMNY), a global leader in medical technology, today announced a landmark collaboration to enhance the national Normative Neuroimaging Library (NNL) with advanced blood-based biomarker data.</description>
</item>
<item>
<title>Oxford Launches Regional Partnership to Drive Equitable, Innovation-Led Growth</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/oxford-launches-regional-partnership-to-drive-equitable-innovation-led-growth</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/oxford-launches-regional-partnership-to-drive-equitable-innovation-led-growth</guid>
<pubDate>Mon, 10 Nov 2025 18:23:00 GMT</pubDate>
<description>OXFORD, United Kingdom, November 10, 2025--A major new regional partnership, Equinox (Equitable Innovation Oxford) has officially launched to establish Oxford as a global centre for innovation and entrepreneurship.</description>
</item>
<item>
<title>KLN Named Exclusive Distributor for Siemens Healthineers</title>
<link>https://6ix.com/company/siemens-healthineers-ag/news/kln-named-exclusive-distributor-for-siemens-healthineers</link>
<guid isPermaLink="true">https://6ix.com/company/siemens-healthineers-ag/news/kln-named-exclusive-distributor-for-siemens-healthineers</guid>
<pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
<description>KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) announces a strategic partnership between its healthcare subsidiary, KLN Medical Limited ('KLN Medical'), and global medical technology leader Siemens Healthineers AG (Stock Code SHL.DE). KLN Medical will serve as the exclusive distributor for Siemens Healthineers' Point-of-Care Testing products in Hong Kong.</description>
</item>
</channel>
</rss>